UK: Three Recent Cases Concerning Supplementary Protection

Last Updated: 4 April 2014
Article by Ian Wood


In three recent cases, the Court of Justice of the European Union ("CJEU") considered the meaning of "protected by the basic patent" under Article 3(a) of SPC Regulation 469/2009 (the "SPC Regulation") and whether it is possible to obtain more than one SPC per patent. The decisions make clear that the purpose of an SPC is to further both research and investment in research and not to extend patent protection by protecting new products containing the same active ingredient in combination with new unidentified active ingredients (see Actavis v Sanofi (C-443/12) below).


Under Article 3 of the SPC Regulation, an SPC may only be granted if, at the date of the SPC application (a) the product in question is protected by a basic patent in force; (b) a valid marketing authorisation has been granted; (c) the product is not already the subject of an SPC certificate; and (d) the marketing authorisation is the first authorisation to place the product on the market as a medicinal product. In making a decision whether to grant an SPC, consideration should be given to the purpose of the SPC Regulation which is to encourage and reward research into pharmaceutical products, such that patent holders are not disadvantaged by the time taken to obtain marketing authorisation and place medicinal products on the market.

The three cases

In the case of Eli Lilly v Human Genome Sciences (C-493/12), Human Genome Sciences ("HGS") had applied for an SPC for its patent based on a marketing authorisation obtained by Eli Lilly.

(In a previous case, Eli Lilly tried to revoke HGS's patent which concerned antibodies which bind to a protein, neutrokine-α (an intercellular mediator in inflammation and immune response). Antibodies that bind specifically to neutrokine-α may inhibit its activity and thus be useful in the treatment of autoimmune diseases. The Supreme Court held that HGS's neutrokine-α patent was valid.)

Lilly argued in the present case that an SPC could not be sought for an active ingredient because the active ingredient was not specified in the patent (that is, in order for an SPC to be granted on the basis of HGS's patent, the patent would have to contain a structural definition of the active ingredients and the claims would have to be more specific).

The CJEU said that it was sufficient that the patent claims included only a functional formula in order for an active ingredient to be regarded as "protected by a basic patent in force" within the meaning of Article 3(a). It is not necessary for the active ingredient to be identified in the claims of the patent by a structural formula .

Eli Lilly and Company Ltd v Human Genome Sciences Inc., Case 493/12, 12 December 2013 .

In Georgetown University v Octrooicentrum Nederland (C-484/12), a case which concerned one basic patent protecting a number of different products, the court considered whether it was possible to obtain an SPC for a single active ingredient protected by a basic patent when an SPC had already been granted for a product containing this active ingredient in combination with others.

Georgetown University's patent related to vaccines for strains of the human papilloma virus.

The question before the court was whether Article 3(c) of the SPC Regulation precluded the holder of a basic patent which protects several pharmaceutical products from being granted an SPC certificate for each of the products. The court said that, yes, it is possible to obtain several SPCs, one for each of those different products, provided that each product is protected as such by the basic patent within the meaning of Article 3(a).

Georgetown University C-484/12, 12 December 2013 .

However, in Actavis v Sanofi (C-443/12), the CJEU said it was not acceptable to extend patent protection of an active ingredient, for which an SPC had already been granted based on a basic patent, by granting a second SPC for a product containing the same active ingredient in combination with a second active ingredient.

Sanofi's patent related to the anti-hypertensive pharmaceutical product irbesartan. The court said that the first SPC covered the active ingredient irbesartan while the second SPC was for the active ingredient in combination with a diuretic not specifically identified in the claims of the patent. The court said both the first and second SPCs were connected with the same product and accordingly, patent protection could not be extended by a second SPC. The patent holder had, by virtue of the first SPC, already been compensated under the SPC Regulation for the delay to market its invention and was not entitled to a second round of compensation by virtue of the second SPC.

Actavis v Sanofi C-443/12

Pay for delay pharma settlements – no respite, more fines from the European Commission

The European Commission has recently handed out further fines to pharmaceutical companies for "Pay for delay" settlement agreements (by which the patent holder pays a generic company to remain out of the market for a period of time, which may include a period after the generic company could legally enter the market), which agreements have become very common in recent years. Pay for delay agreements allow the patent holder to continue earning monopoly profits by sharing part of them with the generic company. The Commission has now fined Johnson & Johnson and Novartis in relation to such agreements.

European Commission press release (IP/13/1233), 10 December 2013.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Ian Wood
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.